Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Further reading == Sarah Steinbach and Reto Neiger: Chronische Nierenerkrankung: In: Hans Lutz et al. (Ed.): Krankheiten der Katze. Enke, 5. Aufl. 2014, ISBN 978-3-8304-1243-4, S. 751–755. Gregory F. Grauer: Chronic renal failure. In: R. W. Nelson und C. G. Couto (Hrsg.): Small animal internal medicine. Mosby, 3. 2003, ISBN 0-323-01724-X, p. 615–623.
The "Peacock Cave" (Pfauenhöhle in German) is also an early cave, although dated slightly later to circa 400 CE, and next located "Cave of the statues" (Cave 77), in the second rocky outcrop just outside of the central valley. It has been carbon dated to mid 4th-end 5th century CE. It is said to be "the most recognizably Indian in the whole Kizil cycle". The paintings echo the Art of Gandhara and the murals of Ajanta Caves. A rectangular vestibule, the vaulted roof of which is now collapsed, preceded the main chamber. The main chamber has a domed ceiling, an innovation first seen in early caves at Bamiyan, and in caves 83 and 84 at Kizil. Numerous statuettes of the Buddha, as well as decorated wooden benches and low display tables were discovered in the antechamber of the cave. In the center of the main chamber, there is a large podium, on which probably stood some major statuary associated with the Buddha. The architecture of the cave displays a marked advancement compared to earlier caves, but is anterior to the "central pillar" cave structure. Several paintings illustrate the life of the Buddha. Only the left wall of the main cella had remained in great part intact by the time Grünwedel visited. The top part of the wall showed four important moments of the life of the Buddha, while celestial observers stand on a balcony above: 1) the Birth of Siddharta and the first Three Steps in which the Buddha appears naked and already tall, 2) the Four Encounters outside of the palace, 3) the Seduction of Mara's daughters, who are turned into old women, and 4) the Assault of Mara.
Several methods have been used to determine the mechanisms of antimicrobial peptide activity. In particular, solid-state NMR studies have provided an atomic-level resolution explanation of membrane disruption by antimicrobial peptides. In more recent years, X-ray crystallography has been used to delineate in atomic detail how the family of plant defensins rupture membranes by identifying key phospholipids in the cell membranes of the pathogen. Human defensins have been thought to act through a similar mechanism, targeting cell membrane lipids as part of their function. In fact human beta-defensin 2 have now been shown to kill the pathogenic fungi Candida albicans through interactions with specific phospholipids. From the computational point of view, Molecular Dynamics simulations can provide detailed information about the structure and dynamics of the peptide-membrane interactions, including the orientation, conformation, and insertion of the peptide in the membrane, as well as specific peptide interactions with lipids, ions and solvent.
Sources: en.wikipedia.org
In humans, it has been used to treat diarrhoea and enteritis caused by bacterial or protozoan infections, including traveler's diarrhoea, cholera, and bacteremic salmonellosis. In 2002, a journal article suggested its use in treatment of H. pylori infections in children. Furazolidone has also been used for giardiasis (due to Giardia lamblia), amoebiasis, and shigellosis, although it is not a first-line treatment. From the early 1970s, it has been used in China to treat peptic ulcers, where the mechanism is treatment of the causative Helicobacter pylori infection. As a veterinary medicine, furazolidone has been used with some success to treat salmonids for Myxobolus cerebralis infections. It has also been used in aquaculture. Since furazolidone is a nitrofuran antibiotic, its use in food animals is currently prohibited by the FDA under the Animal Medicinal Drug Use Clarification Act, 1994. Furazolidone is no longer available in the US. It is used to differentiate micrococci and staphylococci. It is believed to work by crosslinking of DNA.
== Boron-8 == Boron-8 is an isotope of boron that undergoes β+ decay to beryllium-8 with a half-life of 771.9(9) ms. It is the strongest candidate for a halo nucleus with a loosely-bound proton, in contrast to neutron halo nuclei such as lithium-11. Although boron-8 beta decay neutrinos from the Sun make up only about 80 ppm of the total solar neutrino flux, they have a higher energy centered around 10 MeV, and are an important background to dark matter direct detection experiments. They are the first component of the neutrino floor that dark matter direct detection experiments are expected to eventually encounter.
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. Most GLP-1 receptor agonists (liraglutide, exenatide, tirzepatide, pramlintide and others) are administered by injection. Other anti-diabetes medications (including semaglutide as Rybelsus) are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents. (Semaglutide is available both as a pill and as an injection.) There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of the diabetes (Type I vs Type II), the age and situation of the person, as well as other patient factors. Type 1 diabetes is an endocrine disorder characterized by hyperglycemia due to autoimmune destruction of insulin-secreting pancreatic beta cells. Insulin is a hormone needed by cells to take in glucose from the blood. Insufficient levels of insulin due to Type 1 diabetes can lead to chronic hyperglycemia and eventual multiorgan damage, resulting in renal, neurologic, cardiovascular, and other serious complications. The treatment for Type 1 diabetes involves regular insulin injections. Type 2 diabetes, the most common type of diabetes, occurs when cells exhibit insulin resistance and become unable to properly utilize insulin. Insulin resistance requires the pancreas to compensate by increasing insulin production. Once compensation fails, chronic hyperglycemia can manifest and type 2 diabetes develops.
=== Low BMD === Bone Mineral Density (BMD) tends to peak at a young age. When children are younger, they start building up their BMD through their nutrition and through exercise. BMD peaks at around 12.5 years old for girls and around 14 years old for boys. It could be caused by a deficiency in calcium or Vitamin D. Calcium is the main nutrient for bone health. It aids in the structure and density of the bone. Low BMD could be caused by the children not getting the proper exercise for adequate bone growth. Researchers suggest that children should get 20 minutes of vigorous activity 3 to 5 days a week to promote an increase in BMD. Jumping for about 5 minutes a day also stimulates an increase in BMD. Researchers did a 10-year study on the effects of vigorous intensity activity and their bone health/strength. They studied 300 boys and girls. They found that in boys going through puberty (ages 11-13), they experienced a greater bone mass growth. Their bone mass increased during this time because their bones are not ready for the mechanical stress from them growing. However, that is how the bones grow stronger and why their BMD increases. Too much stress on the bones could cause BMD to decrease. Low BMD is dangerous because it can cause disorders inside the bone as the children grow and get older. These disorders can cause the bone to ossify, become brittle, fragile, more easily prone to fractures, and weak. Some of these disorders include osteopenia, osteoporosis, and scoliosis. Scoliosis is very common in children. Low BMD plays a role in the child's scoliosis.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.